GlassScriptPhysician profile
Michael R Cochran
NPI 1831176692
$1,890.68
in general payments reported to CMS, 2019-2025
26 companies · $13.54 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $174 · 2021: $268 · 2022: $24.88 · 2023: $350 · 2024: $92.59 · 2025: $13.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $455.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $357.05 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Novo Nordisk INC | $307.45 | 2019-2023 | Wegovy |
| Abbvie INC. | $274.83 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Janssen Pharmaceuticals, INC | $130.35 | 2019-2020 | |
| Pfizer INC. | $118.17 | 2019-2024 | |
| Astellas Pharma US INC | $116.98 | 2019-2021 | |
| Dexcom, INC. | $83.76 | 2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $59.90 | 2023 | Inspire |
| Abbott Laboratories | $56.01 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $54.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.41 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $40.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.58 | 2021-2023 | Livalo, Seglentis |
| Allergan, INC. | $27.81 | 2019-2020 | |
| Amgen INC. | $25.60 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.16 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.17 | 2020-2022 | |
| Esperion Therapeutics, INC. | $16.29 | 2020 | |
| Phadia US INC. | $16.10 | 2023 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.78 | 2019 | |
| Lilly USA, LLC | $12.16 | 2021 | |
| Daiichi Sankyo INC. | $12.13 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.68 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.66 | 2019 | |
| Biodelivery Sciences International, INC. | $11.37 | 2020 | |
| Merck Sharp & Dohme LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.